• Integration of 3D bioprinting and microfluidics enables fabrication of vascularized tissue constructs, overcoming a major bottleneck in regenerative medicine.
• CRISPR-Cas9 gene editing facilitates personalized cell therapies by enabling precise genetic modifications to enhance cell function and immune compatibility.
• Combinatorial strategies, such as scaffold functionalization with growth factors and dynamic bioreactor culture, significantly improve cell viability and tissue integration.
• Evolving regulatory frameworks and increasing clinical trials signal a promising trajectory for translating platform technologies into clinical practice.